Subscribe

Pfizer Inc. (PFE)

USD24.31 -0.17 (-0.69%)
US NYSE DJIA S&P 500 Healthcare Drug Manufacturers - General
Address 66 Hudson Boulevard East 10001-2192
New York City, NY, US
CEO Albert Bourla
Website pfizer.com
IPO 1972-06-01
CIK 78003 ISIN US7170811035

Explore sections of this company profile

Also trades on Buenos Aires Stock Exchange · PFE.BA (ARS) CBOE CA · PFE.NE (CAD) Deutsche Börse · PFE.DE (EUR) Frankfurt Stock Exchange · PFE.F (EUR) New York Stock Exchange · PFE (USD)
Description

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

News Sentiment (7d)
67 Positive

3 articles

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Date Filing
NAMIC 1995-02-14 View
Warner 1999-11-15 View
Pharmacia 2002-08-14 View
DISTRIBUTIONS 2009-03-27 View

Index membership

IndexAddedRemovedStatus
DJIA 2004-04-08 — Active
S&P 500 1957-03-04 — Active
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD24.31 -0.17 (-0.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
39M
Beta
0.30
Float Shares
5.68B
Free Float %
99.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.53% -2.62% -4.10% -6.02% -0.21% +3.67% +11.80% -30.88% -34.96% -17.94% +5,910.06%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (39 ratings, all time) Hold
Price Targets & DCF
Current price
24.31
Low 24.00 -1.3%
Consensus 27.40 +12.7%
Median 27.00 +11.1%
High 35.00 +44.0%
DCF (Unlevered) 40.74 +67.6%
DCF (Levered) 30.22 +24.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 38% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 9 0
Hold 15 0
Sell 1 0
Strong Sell 2 0
Price Target Summary
Period # Analysts Avg Target
Last Month — —
Last Quarter 5
26.80
+10.2%
Last Year 15
27.87
+14.6%
All Time 57
42.45
+74.6%
Quality scores
Altman Z-Score
2.07
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    -1.7% Q1'26: +5.4% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -3.6% Q1'26: -9.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +7.5% Q1'26: +15.1% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +16.3% Q1'26: +27.9% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +7.3% Q1'26: +9.7% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -0.3% ★ Q1'26: +0.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    4.47× Q1'26: 3.09× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.31) × ERP
WACC = 69% × Ke + 31% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 40.69 Current price: 24.31
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2010
actual 		Dec 2011
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
19 Rev. Ana.
15 EPS Ana. 		Dec 2027
19 Rev. Ana.
14 EPS Ana. 		Dec 2028
23 Rev. Ana.
7 EPS Ana. 		Dec 2029
11 Rev. Ana.
2 EPS Ana. 		Dec 2030
11 Rev. Ana.
5 EPS Ana.
Revenue
67.06B
est: 59.25B (+13.2%)
61.04B
est: 62.14B (-1.8%)
51.58B
est: 50.18B (+2.8%)
49.61B
est: 48.31B (+2.7%)
48.85B
est: 48.39B (+0.9%)
52.82B
est: 52.92B (-0.2%)
52.55B
est: 52.52B (+0.0%)
53.65B
est: 53.53B (+0.2%)
41.17B
est: 51.68B (-20.3%)
41.65B
est: 48.20B (-13.6%)
81.29B
est: 81.76B (-0.6%)
100.33B
est: 100.34B (0.0%)
59.55B
est: 55.17B (+8.0%)
63.63B
est: 63.08B (+0.9%)
62.58B
est: 61.94B (+1.0%)
61.67B
60.51B – 62.80B
-0.4% YoY
59.28B
56.74B – 61.24B
-3.9% YoY
54.83B
54.64B – 55.02B
-7.5% YoY
52.32B
50.36B – 54.17B
-4.6% YoY
53.17B
51.18B – 55.05B
+1.6% YoY
EBITDA
19.57B
est: 16.54B (+18.3%)
22.19B
est: 23.34B (-4.9%)
23.54B
est: 33.42B (-29.6%)
19.14B
est: 18.62B (+2.8%)
15.32B
est: 13.96B (+9.8%)
15.29B
est: 14.21B (+7.6%)
19.84B
est: 16.28B (+21.9%)
19.59B
est: 16.59B (+18.1%)
18.85B
est: 21.36B (-11.7%)
13.17B
est: 14.90B (-11.6%)
30.79B
est: 25.34B (+21.5%)
41.03B
est: 25.25B (+62.5%)
9.56B
est: 16.27B (-41.2%)
18.13B
est: 18.60B (-2.6%)
15.10B
est: 18.26B (-17.3%)
18.19B
17.84B – 18.52B
-0.4% YoY
17.48B
16.73B – 18.06B
-3.9% YoY
16.17B
16.11B – 16.22B
-7.5% YoY
15.43B
14.85B – 15.97B
-4.6% YoY
15.68B
15.09B – 16.23B
+1.6% YoY
EBIT
11.08B
est: 12.02B (-7.8%)
13.16B
est: 17.21B (-23.5%)
17.13B
est: 16.16B (+6.0%)
13.60B
est: 13.12B (+3.6%)
10.16B
est: 11.83B (-14.1%)
9.54B
est: 12.93B (-26.2%)
13.58B
est: 11.63B (+16.8%)
13.20B
est: 11.85B (+11.4%)
13.06B
est: 12.42B (+5.1%)
8.49B
est: 7.41B (+14.5%)
25.60B
est: 18.10B (+41.5%)
35.97B
est: 19.13B (+88.1%)
3.27B
est: 11.76B (-72.2%)
11.11B
est: 13.45B (-17.4%)
10.19B
est: 13.20B (-22.8%)
13.15B
12.90B – 13.39B
-0.4% YoY
12.64B
12.10B – 13.05B
-3.9% YoY
11.69B
11.65B – 11.73B
-7.5% YoY
11.15B
10.73B – 11.55B
-4.6% YoY
11.33B
10.91B – 11.74B
+1.6% YoY
Net Income
8.27B
est: 7.40B (+11.7%)
8.71B
est: 9.43B (-7.7%)
11.65B
est: 21.51B (-45.8%)
9.08B
est: 8.88B (+2.3%)
6.97B
est: 6.29B (+10.8%)
7.22B
est: 6.65B (+8.6%)
21.31B
est: 14.80B (+44.0%)
11.15B
est: 17.08B (-34.7%)
16.27B
est: 13.80B (+17.9%)
9.16B
est: 8.71B (+5.2%)
22.15B
est: 23.99B (-7.7%)
31.37B
est: 18.44B (+70.1%)
2.13B
est: -2.59B (+182.3%)
8.02B
est: 16.84B (-52.4%)
7.77B
est: 17.82B (-56.4%)
16.85B
16.18B – 17.53B
-5.4% YoY
15.84B
14.54B – 17.14B
-6.0% YoY
9.82B
9.66B – 16.26B
-38.0% YoY
12.91B
12.28B – 13.50B
+31.5% YoY
13.57B
12.90B – 14.19B
+5.1% YoY
SGA
19.25B
est: 17.47B (+10.2%)
17.48B
est: 17.96B (-2.6%)
14.19B
est: 14.28B (-0.6%)
13.96B
est: 13.72B (+1.7%)
14.73B
est: 13.75B (+7.1%)
14.76B
est: 14.31B (+3.1%)
14.73B
est: 10.82B (+36.2%)
14.38B
est: 11.02B (+30.5%)
12.67B
est: 13.14B (-3.5%)
11.40B
est: 10.79B (+5.7%)
12.25B
est: 16.84B (-27.2%)
13.12B
est: 10.00B (+31.2%)
14.47B
est: 10.69B (+35.3%)
14.73B
est: 12.23B (+20.5%)
13.35B
est: 12.01B (+11.2%)
11.96B
11.73B – 12.17B
-0.4% YoY
11.49B
11.00B – 11.87B
-3.9% YoY
10.63B
10.59B – 10.66B
-7.5% YoY
10.14B
9.76B – 10.50B
-4.6% YoY
10.31B
9.92B – 10.67B
+1.6% YoY
EPS
1.03
est: 1.81 (-43.1%)
1.11
est: 2.10 (-47.0%)
1.71
est: 2.12 (-19.4%)
1.43
est: 2.14 (-33.1%)
1.13
est: 2.19 (-48.5%)
1.18
est: 2.42 (-51.2%)
3.57
est: 2.60 (+37.4%)
1.90
est: 3.00 (-36.6%)
2.92
est: 2.97 (-1.6%)
1.65
est: 2.83 (-41.8%)
3.95
est: 4.21 (-6.0%)
5.59
est: 6.50 (-14.0%)
0.38
est: -0.46 (+181.9%)
1.42
est: 2.93 (-51.5%)
1.36
est: 3.12 (-56.4%)
2.96
2.85 – 3.08
-5.0% YoY
2.84
2.56 – 3.01
-4.0% YoY
2.46
1.70 – 2.86
-13.7% YoY
2.27
2.16 – 2.37
-7.5% YoY
2.39
2.27 – 2.50
+5.1% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-04-29 Citigroup Neutral Neutral Maintain
2026-04-20 RBC Capital Underperform Underperform Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B+ 3/5 4/5 4/5 4/5 1/5 2/5 3/5
2026-05-08 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-05-07 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-05-06 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-05-05 B+ 3/5 4/5 3/5 4/5 1/5 3/5 3/5
2026-05-04 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-05-01 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-30 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-29 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-24 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-15 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
9.70B
OE per share TTM
1.70
Owner's Yield
6.45%
Maintenance CapEx ratio
9.12%
Maint CapEx / Avg PPE
25.9%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1,103
Total invested
4.92B
Insider transactions (90d)
28
Beneficial owners (>5%)
25
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 ”) 2.96B 32.00% 2.96B — 2.96B 10.00 CO Delaware 2023-10-10 ↗
2 The Vanguard Group - 23-1945930 465.27M 8.29% — 8.87M 442.21M 23.06M IA — 2022-02-10 ↗
3 (1) BlackRock, Inc. 409.99M 7.30% 362.55M — 409.99M — HC Delaware 2022-02-01 ↗
4 STATE STREET CORPORATION 285.77M 5.09% — 210.99M — 285.08M HC BOSTON, MASSACHUSETTS 2022-02-14 ↗
5 PFIZER INC. 13-5315170 9.55M 8.10% 9.55M — 9.55M — CO Delaware 2022-06-29 ↗
6 Arena Pharmaceuticals, Inc. 3.98M 23.10% — 3.98M — 10.00 CO DELAWARE 2022-03-21 ↗
7 Pfizer Inc. (“Pfizer”) 3.98M 23.10% — 3.98M — 10.00 CO DELAWARE 2022-03-21 ↗
8 Pfizer Inc.        13-5315170 2.99M 9.13% — 2.99M — — CO — 2022-02-11 ↗
9 Pfizer Ventures (US) LLC     82-5524518 2.99M 9.13% — 2.99M — — OO — 2022-02-11 ↗
10 Pfizer Inc. 2.97M 10.78% 2.97M — 2.97M — CO Delaware 2023-03-30 ↗
11 PFIZER INC.           13-5315170 2.53M 6.70% 2.53M — 2.53M — CO Delaware 2022-06-28 ↗
12 Pfizer Inc.       13-5315170 2.34M 4.75% 11.8K 2.33M 11.8K — CO Delaware 2022-02-14 ↗
13 (VOLUNTARY) 98-1625134 2.33M 4.73% — 2.33M — — CO Netherlands 2022-02-14 ↗
14 Pfizer Ventures (US) LLC 2.24M 7.00% — 2.24M — — OO Delaware 2021-02-16 ↗
15 ( 81-4343957 1.88M 4.65% — 1.88M — — OO Citizenship or Place of Organization Delaware 2022-02-14 ↗
16 Pfizer Ventures (US) LLC        82-5524518 1.88M 3.19% — 1.88M — — OO — 2022-02-11 ↗
17 ( 13-5315170 1.79M 4.54% 1.79M — 1.79M — CO — 2022-02-14 ↗
18 Pfizer Inc.      13-5315170 1.68M 3.81% 1.68M — 1.68M — CO Delaware 2022-02-11 ↗
19 Pfizer Inc.       13-5315170 1.37M 3.88% — 1.37M — — CO — 2022-02-11 ↗
20 Pfizer Ventures (US) LLC      82-5524518 1.37M 3.88% — 1.37M — — OO — 2022-02-11 ↗
21 Anacor Pharmaceuticals, LLC      25-1854385 1.36M 7.02% — 1.36M — — OO Delaware 2023-02-13 ↗
22 Pfizer Inc.          13-5315170 1.36M 7.02% — 1.36M — — CO Delaware 2023-02-13 ↗
23 Pfizer Inc.           13-5315170 600.0K 2.01% — 600.0K — — CO — 2022-02-14 ↗
24 ( 82-5524518 365.0K 0.90% — 365.0K — — OO Citizenship or Place of Organization Delaware 2022-02-14 ↗
25 Pfizer Ventures (US) LLC    82-5524518 341.7K 1.06% — 341.7K — — OO — 2022-02-11 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
1,103
-1,923 vs prev Q
New positions
79
Closed positions
1,901
Increased
557
Reduced
408
Put/Call ratio
1.89
Calls held
217.4K
Puts held
410.4K
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 VANGUARD GROUP INC 541.35M +7.0M (+1.3%) 13.48B -134.8M (-1.0%) 9.53% +0.127 pp 0.20% -0.008 pp USD25.76 -3.3% 84 qtrs —
2 BLACKROCK, INC. 493.06M -4.4M (-0.9%) 12.28B -397.4M (-3.1%) 8.68% -0.074 pp 0.21% -0.014 pp USD28.49 -12.6% 6 qtrs —
3 STATE STREET CORP 300.45M +1.4M (+0.5%) 7.48B -139.7M (-1.8%) 5.29% +0.026 pp 0.25% -0.013 pp USD29.18 -14.7% 51 qtrs —
4 GEODE CAPITAL MANAGEMENT, LLC 130.19M +1.2M (+0.9%) 3.24B -43.4M (-1.3%) 2.29% +0.022 pp 0.20% -0.010 pp USD31.58 -21.2% 78 qtrs —
5 MORGAN STANLEY 89.11M +14.3M (+19.2%) 2.22B +313.8M (+16.5%) 1.57% +0.253 pp 0.13% +0.017 pp USD35.40 -29.7% 51 qtrs —
6 NORGES BANK 73.53M +73.5M (+100.0%) 1.83B +1.8B (+100.0%) 1.29% +1.294 pp 0.20% +0.196 pp USD24.90 +0.0% 1 qtrs NEW
7 NORTHERN TRUST CORP 63.25M -769.2K (-1.2%) 1.57B -56.3M (-3.5%) 1.11% -0.013 pp 0.20% -0.008 pp USD27.98 -11.0% 51 qtrs —
8 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 55.87M -1.7M (-3.0%) 1.39B -76.1M (-5.2%) 0.98% -0.030 pp 0.45% -0.006 pp USD34.52 -27.9% 51 qtrs —
9 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 54.51M +— (+0.0%) 1.36B -31.6M (-2.3%) 0.96% +0.000 pp 1.07% -0.092 pp USD43.63 -42.9% 108 qtrs —
10 WELLINGTON MANAGEMENT GROUP LLP 52.09M -8.4M (-13.8%) 1.30B -243.4M (-15.8%) 0.92% -0.147 pp 0.23% -0.042 pp USD32.71 -23.9% 81 qtrs —
11 FISHER ASSET MANAGEMENT, LLC 51.95M +2.7M (+5.4%) 1.29B +37.7M (+3.0%) 0.91% +0.047 pp 0.44% -0.013 pp USD25.79 -3.5% 57 qtrs —
12 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 50.54M +410.1K (+0.8%) 1.26B -18.9M (-1.5%) 0.89% +0.008 pp 0.20% -0.008 pp USD31.89 -21.9% 100 qtrs —
13 BANK OF AMERICA CORP /DE/ 48.78M +4.4M (+9.8%) 1.21B +83.0M (+7.3%) 0.86% +0.077 pp 0.09% +0.012 pp USD30.37 -18.0% 52 qtrs —
14 BANK OF NEW YORK MELLON CORP 48.51M +13.6M (+38.9%) 1.21B +317.9M (+35.7%) 0.85% +0.239 pp 0.22% +0.042 pp USD29.94 -16.8% 66 qtrs —
15 AMUNDI 47.06M +5.6M (+13.4%) 1.17B +75.5M (+6.9%) 0.83% +0.098 pp 0.32% -0.034 pp USD33.00 -24.5% 19 qtrs —
16 LEGAL & GENERAL GROUP PLC 42.86M +1.1M (+2.7%) 1.07B +3.8M (+0.4%) 0.75% +0.020 pp 0.24% -0.002 pp USD29.59 -15.8% 75 qtrs —
17 GOLDMAN SACHS GROUP INC 40.06M +7.2M (+22.1%) 997.38M +161.2M (+19.3%) 0.70% +0.128 pp 0.12% +0.020 pp USD29.48 -15.5% 73 qtrs —
18 DIMENSIONAL FUND ADVISORS LP 36.13M -205.8K (-0.6%) 899.66M -25.4M (-2.8%) 0.64% -0.003 pp 0.19% -0.010 pp USD30.37 -18.0% 51 qtrs —
19 ROYAL BANK OF CANADA 35.87M -3.4M (-8.6%) 893.17M -106.4M (-10.6%) 0.63% -0.059 pp 0.15% -0.019 pp USD30.47 -18.3% 51 qtrs —
20 UBS ASSET MANAGEMENT AMERICAS INC 35.71M +1.5M (+4.4%) 889.25M +18.0M (+2.1%) 0.63% +0.027 pp 0.19% -0.001 pp USD29.55 -15.7% 90 qtrs —
21 DEUTSCHE BANK AG\ 30.90M -2.2M (-6.7%) 769.38M -74.8M (-8.9%) 0.54% -0.039 pp 0.25% -0.032 pp USD31.91 -22.0% 50 qtrs —
22 SUSQUEHANNA INTERNATIONAL GROUP, LLP 28.50M +3.6M (+14.3%) 709.56M +74.5M (+11.7%) 0.50% +0.063 pp 0.08% +0.009 pp USD29.32 -15.1% 51 qtrs —
23 INVESCO LTD. 27.26M -3.1M (-10.1%) 678.78M -94.2M (-12.2%) 0.48% -0.054 pp 0.10% -0.018 pp USD31.00 -19.7% 57 qtrs —
24 FRANKLIN RESOURCES INC 25.16M +94.2K (+0.4%) 626.59M -12.2M (-1.9%) 0.44% +0.002 pp 0.15% -0.006 pp USD31.54 -21.1% 51 qtrs —
25 JPMORGAN CHASE & CO 23.34M -4.9M (-17.4%) 581.20M -139.0M (-19.3%) 0.41% -0.086 pp 0.04% -0.007 pp USD38.71 -35.7% 51 qtrs —
26 CAPITAL WORLD INVESTORS 21.43M +7.3M (+51.5%) 533.70M +173.2M (+48.1%) 0.38% +0.128 pp 0.07% +0.023 pp USD34.16 -27.1% 50 qtrs —
27 FEDERATED HERMES, INC. 20.25M +1.6M (+8.8%) 504.17M +30.1M (+6.3%) 0.36% +0.029 pp 0.84% +0.005 pp USD35.74 -30.3% 54 qtrs —
28 VICTORY CAPITAL MANAGEMENT INC 19.80M +3.6M (+22.3%) 492.93M +79.5M (+19.2%) 0.35% +0.064 pp 0.28% +0.036 pp USD26.82 -7.2% 50 qtrs —
29 CITADEL ADVISORS LLC 18.93M +4.4M (+30.5%) 471.35M +101.9M (+27.6%) 0.33% +0.078 pp 0.07% +0.015 pp USD32.69 -23.8% 38 qtrs —
30 FIRST TRUST ADVISORS LP 18.73M +495.8K (+2.7%) 466.41M +1.8M (+0.4%) 0.33% +0.009 pp 0.34% -0.007 pp USD35.11 -29.1% 51 qtrs —
31 WELLS FARGO & COMPANY/MN 18.70M -774.0K (-4.0%) 465.60M -30.6M (-6.2%) 0.33% -0.014 pp 0.08% -0.010 pp USD30.05 -17.1% 57 qtrs —
32 AMERIPRISE FINANCIAL INC 18.39M +18.0K (+0.1%) 458.13M -10.0M (-2.1%) 0.32% +0.000 pp 0.10% -0.004 pp USD30.42 -18.1% 51 qtrs —
33 BARCLAYS PLC 18.13M -8.9M (-33.0%) 451.54M -332.3M (-42.4%) 0.32% -0.157 pp 0.11% -0.093 pp USD28.73 -13.3% 51 qtrs —
34 LSV ASSET MANAGEMENT 17.50M +579.4K (+3.4%) 435.82M +4.6M (+1.1%) 0.31% +0.010 pp 0.95% -0.002 pp USD24.82 +0.3% 59 qtrs —
35 UBS GROUP AG 16.80M -5.0M (-22.9%) 418.27M -137.1M (-24.7%) 0.30% -0.088 pp 0.07% -0.019 pp USD32.82 -24.1% 45 qtrs —
36 BNP PARIBAS ARBITRAGE, SNC 16.53M +6.9M (+71.1%) 411.56M +165.4M (+67.2%) 0.29% +0.121 pp 0.19% +0.055 pp USD28.10 -11.4% 51 qtrs —
37 JANE STREET GROUP, LLC 16.44M +7.1M (+75.7%) 409.33M +171.0M (+71.7%) 0.29% +0.125 pp 0.06% +0.026 pp USD27.20 -8.5% 6 qtrs —
38 PACER ADVISORS, INC. 16.19M -1.4M (-7.9%) 403.21M -44.6M (-10.0%) 0.29% -0.024 pp 1.03% -0.098 pp USD25.77 -3.4% 41 qtrs —
39 HSBC HOLDINGS PLC 15.93M -1.3M (-7.6%) 397.02M -38.6M (-8.9%) 0.28% -0.023 pp 0.20% -0.038 pp USD34.12 -27.0% 56 qtrs —
40 SWISS NATIONAL BANK 15.58M -808.5K (-4.9%) 387.94M -29.6M (-7.1%) 0.27% -0.014 pp 0.23% -0.011 pp USD32.59 -23.6% 51 qtrs —
41 SUMITOMO MITSUI TRUST HOLDINGS, INC. 15.13M -483.5K (-3.1%) 376.77M -21.1M (-5.3%) 0.27% -0.008 pp 0.22% -0.008 pp USD26.90 -7.4% 59 qtrs —
42 UNISPHERE ESTABLISHMENT 14.65M +250.0K (+1.7%) 364.79M -2.1M (-0.6%) 0.26% +0.005 pp 2.73% -0.150 pp USD28.25 -11.9% 9 qtrs —
43 CITIGROUP INC 14.27M +7.1M (+97.7%) 355.20M +171.4M (+93.2%) 0.25% +0.124 pp 0.16% +0.075 pp USD27.42 -9.2% 108 qtrs —
44 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 13.97M -2.7M (-16.4%) 347.95M -78.2M (-18.3%) 0.25% -0.048 pp 0.20% -0.056 pp USD30.26 -17.7% 58 qtrs —
45 NATIONAL PENSION SERVICE 13.44M +498.3K (+3.9%) 334.64M +4.9M (+1.5%) 0.24% +0.009 pp 0.25% -0.008 pp USD32.53 -23.5% 46 qtrs —
46 VAN ECK ASSOCIATES CORP 13.34M -4.8M (-26.5%) 332.23M -130.4M (-28.2%) 0.23% -0.085 pp 0.27% -0.155 pp USD31.94 -22.0% 57 qtrs —
47 LPL FINANCIAL LLC 13.27M +1.1M (+9.3%) 330.41M +21.1M (+6.8%) 0.23% +0.020 pp 0.09% +0.000 pp USD32.21 -22.7% 51 qtrs —
48 NUVEEN, LLC 13.16M -676.9K (-4.9%) 327.79M -24.9M (-7.1%) 0.23% -0.012 pp 0.09% -0.007 pp USD25.34 -1.7% 4 qtrs —
49 MARSHALL WACE, LLP 12.66M +5.7M (+81.4%) 315.28M +137.4M (+77.3%) 0.22% +0.100 pp 0.29% +0.107 pp USD25.28 -1.5% 20 qtrs —
50 PRICE T ROWE ASSOCIATES INC /MD/ 12.47M +430.9K (+3.6%) 310.62M +3.7M (+1.2%) 0.22% +0.008 pp 0.03% +0.001 pp USD32.96 -24.5% 75 qtrs —
51 SCHRODER INVESTMENT MANAGEMENT GROUP 12.35M -25.3K (-0.2%) 307.55M -7.8M (-2.5%) 0.22% 0.000 pp 0.24% -0.011 pp USD31.46 -20.9% 51 qtrs —
52 FMR LLC 12.28M -2.1M (-14.8%) 305.65M -61.3M (-16.7%) 0.22% -0.037 pp 0.02% -0.004 pp USD34.09 -27.0% 70 qtrs —
53 MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. 12.08M +685.1K (+6.0%) 304.21M +13.8M (+4.8%) 0.21% +0.012 pp 0.21% -0.003 pp USD32.15 -22.6% 58 qtrs —
54 RAYMOND JAMES FINANCIAL INC 11.49M -9.5K (-0.1%) 286.05M -6.9M (-2.3%) 0.20% 0.000 pp 0.09% -0.005 pp USD26.41 -5.7% 5 qtrs —
55 ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. 9.87M -1.5M (-13.4%) 245.78M -44.7M (-15.4%) 0.17% -0.027 pp 0.35% -0.071 pp USD27.54 -9.6% 74 qtrs —
56 AQR CAPITAL MANAGEMENT LLC 9.82M +314.2K (+3.3%) 244.51M +13.5M (+5.9%) 0.17% +0.006 pp 0.13% -0.020 pp USD26.80 -7.1% 90 qtrs —
57 SQUAREPOINT OPS LLC 9.68M -596.9K (-5.8%) 241.11M -20.8M (-8.0%) 0.17% -0.010 pp 0.26% -0.007 pp USD25.94 -4.0% 41 qtrs —
58 BANK OF MONTREAL /CAN/ 9.64M +400.1K (+4.3%) 240.10M +4.6M (+2.0%) 0.17% +0.007 pp 0.08% -0.007 pp USD34.70 -28.2% 51 qtrs —
59 DIAMOND HILL CAPITAL MANAGEMENT INC 9.44M -1.5M (-13.6%) 235.04M -43.3M (-15.6%) 0.17% -0.026 pp 1.20% -0.117 pp USD27.79 -10.4% 88 qtrs —
60 STIFEL FINANCIAL CORP 9.28M -76.5K (-0.8%) 231.01M -7.3M (-3.1%) 0.16% -0.001 pp 0.21% -0.010 pp USD34.52 -27.9% 48 qtrs —
61 FIL LTD 9.25M -2.6M (-22.2%) 230.35M -72.4M (-23.9%) 0.16% -0.046 pp 0.17% -0.066 pp USD28.15 -11.5% 66 qtrs —
62 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 9.21M -259.9K (-2.7%) 229.25M -12.0M (-5.0%) 0.16% -0.005 pp 0.23% -0.018 pp USD29.37 -15.2% 52 qtrs —
63 KBC GROUP NV 9.19M +706.4K (+8.3%) 228.92M +12.7M (+5.9%) 0.16% +0.013 pp 0.52% +0.003 pp USD27.72 -10.2% 68 qtrs —
64 RHUMBLINE ADVISERS 8.81M -217.3K (-2.4%) 219.37M -10.6M (-4.6%) 0.16% -0.004 pp 0.18% -0.007 pp USD31.57 -21.1% 51 qtrs —
65 JANUS HENDERSON GROUP PLC 8.79M +7.5M (+577.5%) 218.82M +185.8M (+562.3%) 0.15% +0.132 pp 0.10% +0.083 pp USD25.79 -3.5% 87 qtrs —
66 ENVESTNET ASSET MANAGEMENT INC 8.65M -1.4M (-13.8%) 215.34M -40.2M (-15.7%) 0.15% -0.024 pp 0.06% -0.010 pp USD35.20 -29.3% 51 qtrs —
67 BRANDES INVESTMENT PARTNERS, LP 8.63M +216.4K (+2.6%) 214.87M +509.2K (+0.2%) 0.15% +0.004 pp 1.64% -0.084 pp USD28.10 -11.4% 70 qtrs —
68 BALYASNY ASSET MANAGEMENT L.P. 8.54M +4.0M (+89.1%) 212.77M +97.6M (+84.8%) 0.15% +0.071 pp 0.27% +0.124 pp USD24.94 -0.2% 18 qtrs —
69 DEKABANK DEUTSCHE GIROZENTRALE 7.40M +— (+0.0%) 208.04M +31.8M (+18.0%) 0.13% +0.000 pp 0.36% +0.063 pp USD39.53 -37.0% 66 qtrs —
70 NEW YORK STATE COMMON RETIREMENT FUND 7.97M -255.1K (-3.1%) 198.43M -11.1M (-5.3%) 0.14% -0.004 pp 0.26% -0.006 pp USD18.41 +35.3% 103 qtrs —
71 NEUBERGER BERMAN GROUP LLC 7.36M -1.7M (-18.3%) 183.33M -46.0M (-20.1%) 0.13% -0.029 pp 0.14% -0.031 pp USD27.79 -10.4% 51 qtrs —
72 HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 7.20M -2.3M (-23.9%) 179.16M -61.8M (-25.7%) 0.13% -0.040 pp 0.30% -0.137 pp USD26.85 -7.3% 25 qtrs —
73 PNC FINANCIAL SERVICES GROUP, INC. 7.19M -241.1K (-3.2%) 179.09M -10.3M (-5.4%) 0.13% -0.004 pp 0.10% -0.017 pp USD28.13 -11.5% 51 qtrs —
74 — 6.84M +1.1M (+20.0%) 170.35M +25.0M (+17.2%) 0.12% +0.020 pp 0.87% +0.112 pp USD27.81 -10.5% 44 qtrs —
75 SUSQUEHANNA ADVISORS GROUP, INC. 6.80M +1.8M (+36.0%) 169.32M +41.9M (+32.9%) 0.12% +0.032 pp 2.81% +0.858 pp USD24.57 +1.3% 5 qtrs —
76 GREAT WEST LIFE ASSURANCE CO /CAN/ 6.65M -1.7M (-20.3%) 165.71M -33.1M (-16.7%) 0.12% -0.030 pp 0.29% +0.004 pp USD30.51 -18.4% 63 qtrs —
77 ALLIANCEBERNSTEIN L.P. 6.57M -110.1K (-1.6%) 163.68M -6.6M (-3.9%) 0.12% -0.002 pp 0.05% -0.002 pp USD33.89 -26.5% 61 qtrs —
78 PZENA INVESTMENT MANAGEMENT LLC 6.53M -88.8K (-1.3%) 162.52M -6.0M (-3.6%) 0.11% -0.002 pp 0.49% -0.058 pp USD30.77 -19.1% 45 qtrs —
79 PRUDENTIAL FINANCIAL INC 6.49M -3.0M (-32.0%) 161.49M -81.4M (-33.5%) 0.11% -0.054 pp 0.20% -0.094 pp USD30.36 -18.0% 85 qtrs —
80 PRINCIPAL FINANCIAL GROUP INC 6.31M +169.0K (+2.8%) 157.04M +649.4K (+0.4%) 0.11% +0.003 pp 0.08% +0.001 pp USD30.83 -19.2% 81 qtrs —
81 BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. 5.87M -8.1K (-0.1%) 146.26M -3.1M (-2.1%) 0.10% 0.000 pp 0.17% -0.219 pp USD27.40 -9.1% 51 qtrs —
82 ALLIANZ ASSET MANAGEMENT GMBH 5.72M -467.4K (-7.6%) 142.48M -15.2M (-9.7%) 0.10% -0.008 pp 0.14% -0.032 pp USD29.76 -16.3% 51 qtrs —
83 NATIXIS 5.63M +2.3M (+69.3%) 140.18M +55.4M (+65.4%) 0.10% +0.041 pp 0.50% +0.105 pp USD26.34 -5.5% 51 qtrs —
84 ARTEMIS INVESTMENT MANAGEMENT LLP 5.61M +5.0M (+849.6%) 139.69M +124.6M (+828.0%) 0.10% +0.088 pp 1.69% +1.500 pp USD25.13 -0.9% 7 qtrs —
85 D. E. SHAW & CO., INC. 5.59M +322.0K (+6.1%) 139.13M +5.0M (+3.7%) 0.10% +0.006 pp 0.08% +0.001 pp USD28.50 -12.6% 53 qtrs —
86 SWEDBANK AB 5.49M +627.4K (+12.9%) 136.71M +12.8M (+10.3%) 0.10% +0.011 pp 0.13% +0.007 pp USD36.59 -31.9% 20 qtrs —
87 SG AMERICAS SECURITIES, LLC 5.41M +3.8M (+240.2%) 134.78M +94.2M (+232.4%) 0.10% +0.067 pp 0.17% +0.035 pp USD25.09 -0.8% 51 qtrs —
88 ENSIGN PEAK ADVISORS, INC 5.36M +233.8K (+4.6%) 133.40M +2.8M (+2.2%) 0.09% +0.004 pp 0.24% +0.021 pp USD34.66 -28.2% 25 qtrs —
89 CANADA PENSION PLAN INVESTMENT BOARD 5.30M -1.7M (-24.7%) 132.05M -47.5M (-26.4%) 0.09% -0.031 pp 0.09% -0.038 pp USD33.47 -25.6% 52 qtrs —
90 VOYA INVESTMENT MANAGEMENT LLC 5.27M -15.3K (-0.3%) 131.14M -3.4M (-2.6%) 0.09% 0.000 pp 0.13% -0.005 pp USD27.90 -10.8% 51 qtrs —
91 RUSSELL INVESTMENTS GROUP, LTD. 5.22M +911.3K (+21.2%) 130.05M +20.6M (+18.8%) 0.09% +0.016 pp 0.14% +0.017 pp USD30.28 -17.8% 37 qtrs —
92 ABRDN PLC 5.21M -664.8K (-11.3%) 129.62M -15.2M (-10.5%) 0.09% -0.012 pp 0.20% -0.028 pp USD29.75 -16.3% 34 qtrs —
93 EMPOWER ADVISORY GROUP, LLC 5.14M +108.3K (+2.2%) 128.08M -224.4K (-0.2%) 0.09% +0.002 pp 0.35% -0.010 pp USD32.98 -24.5% 12 qtrs —
94 STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 5.01M -262.2K (-5.0%) 124.79M -9.6M (-7.1%) 0.09% -0.005 pp 0.22% -0.014 pp USD27.50 -9.5% 51 qtrs —
95 NATIONAL BANK OF CANADA /FI/ 4.90M +97.5K (+2.0%) 122.05M -367.5K (-0.3%) 0.09% +0.002 pp 0.11% -0.011 pp USD31.51 -21.0% 17 qtrs —
96 NORDEA INVESTMENT MANAGEMENT AB 4.82M -1.3M (-20.9%) 120.07M -28.2M (-19.0%) 0.08% -0.022 pp 0.10% -0.027 pp USD28.03 -11.2% 88 qtrs —
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
14
Sells
0
Shares acquired
85.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+85,507
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2031-03-03 Hancock Dennis P Officer — — Stock Appreciation Rights 15,748 26.58 418.6K 0 D ↗
2031-02-27 Hancock Dennis P Officer — — Stock Appreciation Rights 11,867 26.89 319.1K 0 D ↗
2030-03-04 Hancock Dennis P Officer — — Stock Appreciation Rights 33,051 25.75 851.1K 0 D ↗
2030-02-23 Hancock Dennis P Officer — — Stock Appreciation Rights 8,610 42.30 364.2K 0 D ↗
2030-02-23 BOSHOFF CHRISTOFFEL Officer — D Stock Appreciation Rights 17,984 42.30 760.7K 0 — ↗
2029-02-24 Hancock Dennis P Officer — — Stock Appreciation Rights 6,868 45.96 315.7K 0 D ↗
2029-02-24 BOSHOFF CHRISTOFFEL Officer — D Stock Appreciation Rights 10,222 45.96 469.8K 0 — ↗
2028-02-25 McDermott Michael Officer — D Stock Appreciation Rights 32,769 33.82 1.11M 0 — ↗
2028-02-25 Hancock Dennis P Officer — — Stock Appreciation Rights 9,102 33.82 307.8K 0 D ↗
2028-02-25 BOSHOFF CHRISTOFFEL Officer — D Stock Appreciation Rights 16,688 33.82 564.4K 0 — ↗
2027-02-27 SAHNI PAYAL Officer — D Stock Appreciation Rights 15,509 34.10 528.9K 0 — ↗
2027-02-27 McDermott Michael Officer — D Stock Appreciation Rights 41,485 31.31 1.30M 0 — ↗
2027-02-27 Hancock Dennis P Officer — — Stock Appreciation Rights 9,603 31.31 300.7K 0 D ↗
2027-02-27 DAMICO JENNIFER B. Officer — D Stock Appreciation Rights 18,246 34.10 622.2K 0 — ↗
2027-02-27 Carapezzi William R JR Officer — D Stock Appreciation Rights 21,895 34.10 746.6K 0 — ↗
2027-02-27 BOSHOFF CHRISTOFFEL Officer — D Stock Appreciation Rights 21,127 31.31 661.5K 0 — ↗
2026-04-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 22 0.00 — 760,229 D ↗
2026-04-23 Taraporevala Cyrus Director A-Award A Phantom Stock Units 7,687 0.00 — 34,826 D ↗
2026-04-23 SMITH JAMES C Director A-Award A Phantom Stock Units 7,687 0.00 — 178,111 D ↗
2026-04-23 Quincey James Director A-Award A Phantom Stock Units 7,687 0.00 — 85,004 D ↗
2026-04-23 NORA JOHNSON SUZANNE M Director A-Award A Phantom Stock Units 7,687 0.00 — 116,983 D ↗
2026-04-23 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 7,687 0.00 — 195,612 D ↗
2026-04-23 LITTMAN DAN R. Director A-Award A Phantom Stock Units 7,687 0.00 — 74,534 D ↗
2026-04-23 Gottlieb Scott Director A-Award A Phantom Stock Units 7,687 0.00 — 57,002 D ↗
2026-04-23 Echevarria Joseph Director A-Award A Phantom Stock Units 7,687 0.00 — 161,085 D ↗
2026-04-23 Desmond-Hellmann Susan Director A-Award A Phantom Stock Units 7,687 0.00 — 45,636 D ↗
2026-04-23 Buckley Mortimer J Director A-Award A Phantom Stock Units 7,687 0.00 — 24,391 D ↗
2026-04-23 BLAYLOCK RONALD E Director A-Award A Phantom Stock Units 7,687 0.00 — 84,013 D ↗
2026-04-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 22 0.00 — 760,070 D ↗
2026-04-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 911 0.00 — 760,090 D ↗
2026-04-01 Hancock Dennis P Officer — — Common Stock 0 0.00 — 45,097 D ↗
2026-03-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 21 0.00 — 759,049 D ↗
2026-03-27 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,387 0.00 — 27,140 D ↗
2026-03-27 SMITH JAMES C Director A-Award A Phantom Stock Units 1,664 0.00 — 170,425 D ↗
2026-03-27 Quincey James Director A-Award A Phantom Stock Units 1,433 0.00 — 77,318 D ↗
2026-03-27 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 1,849 0.00 — 187,925 D ↗
2026-03-27 Echevarria Joseph Director A-Award A Phantom Stock Units 1,710 0.00 — 153,398 D ↗
2026-03-27 Buckley Mortimer J Director A-Award A Phantom Stock Units 1,387 0.00 — 16,705 D ↗
2026-03-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 1,630 0.00 — 759,400 D ↗
2026-03-04 DAMICO JENNIFER B. Officer F-InKind D Common Stock 826 26.62 22.0K 32,934 D ↗
2026-03-03 de Germay Alexandre Officer A-Award A Stock Appreciation Rights 194,883 26.58 5.18M 194,883 D ↗
2026-03-03 SAHNI PAYAL Officer A-Award A Stock Appreciation Rights 108,268 26.58 2.88M 108,268 D ↗
2026-03-03 McDermott Michael Officer A-Award A Stock Appreciation Rights 151,576 26.58 4.03M 151,576 D ↗
2026-03-03 MALIK AAMIR Officer A-Award A Stock Appreciation Rights 194,883 26.58 5.18M 194,883 D ↗
2026-03-03 LANKLER DOUGLAS M Officer A-Award A Stock Appreciation Rights 194,883 26.58 5.18M 194,883 D ↗
2026-03-03 Fonseca Lidia Officer A-Award A Stock Appreciation Rights 82,284 26.58 2.19M 82,284 D ↗
2026-03-03 Denton David M Officer A-Award A Stock Appreciation Rights 216,537 26.58 5.76M 216,537 D ↗
2026-03-03 DAMICO JENNIFER B. Officer A-Award A Common Stock 5,408 0.00 — 33,760 D ↗
2026-03-03 Baum Andrew Officer A-Award A Stock Appreciation Rights 303,151 26.58 8.06M 303,151 D ↗
2026-03-03 BOURLA ALBERT Director / Officer A-Award A Stock Appreciation Rights 708,666 26.58 18.84M 708,666 D ↗
2026-03-03 BOSHOFF CHRISTOFFEL Officer A-Award A Stock Appreciation Rights 259,844 26.58 6.91M 259,844 D ↗
2026-02-28 SAHNI PAYAL Officer — D Stock Appreciation Rights 10,775 43.35 467.1K 0 — ↗
2026-02-28 McDermott Michael Officer — D Stock Appreciation Rights 16,011 38.71 619.8K 0 — ↗
2026-02-28 DAMICO JENNIFER B. Officer — D Stock Appreciation Rights 7,606 43.35 329.7K 0 — ↗
2026-02-28 Carapezzi William R JR Officer — D Stock Appreciation Rights 15,211 43.35 659.4K 0 — ↗
2026-02-28 BOSHOFF CHRISTOFFEL Officer — D Stock Appreciation Rights 12,009 38.71 464.9K 0 — ↗
2026-02-27 DAMICO JENNIFER B. Officer F-InKind D Common Stock 655 27.65 18.1K 12,041 D ↗
2026-02-26 McDermott Michael Officer F-InKind D Common Stock 3,503 27.10 94.9K 74,308 D ↗
2026-02-25 SAHNI PAYAL Officer M-Exempt A Common Stock 56,888 33.82 1.92M 82,816 D ↗
2026-02-25 McDermott Michael Officer M-Exempt D Stock Appreciation Rights 37,925 33.82 1.28M 0 D ↗
2026-02-25 LANKLER DOUGLAS M Officer M-Exempt A Common Stock 122,907 33.82 4.16M 282,186 D ↗
2026-02-25 Fonseca Lidia Officer M-Exempt D Stock Appreciation Rights 56,888 33.82 1.92M 0 D ↗
2026-02-25 DAMICO JENNIFER B. Officer M-Exempt A Common Stock 17,558 33.82 593.8K 29,744 D ↗
2026-02-25 BOURLA ALBERT Director / Officer M-Exempt A Common Stock 491,626 33.82 16.63M 864,215 D ↗
2026-02-25 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 6,833 27.09 185.1K 161,379 D ↗
2026-02-23 DAMICO JENNIFER B. Officer F-InKind D Common Stock 419 27.06 11.3K 12,186 D ↗
2026-02-23 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 816 27.06 22.1K 154,829 D ↗
2026-02-12 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 2,883 0.00 — 757,286 D ↗
2026-01-30 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 12,887 26.44 340.7K 155,645 D ↗
2026-01-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 79 0.00 — 743,136 D ↗
2025-12-31 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,506 0.00 — 25,350 D ↗
2025-12-31 SMITH JAMES C Director A-Award A Phantom Stock Units 1,807 0.00 — 166,120 D ↗
2025-12-31 Quincey James Director A-Award A Phantom Stock Units 1,556 0.00 — 74,697 D ↗
2025-12-31 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 2,008 0.00 — 183,164 D ↗
2025-12-31 Echevarria Joseph Director A-Award A Phantom Stock Units 1,857 0.00 — 149,314 D ↗
2025-12-31 Buckley Mortimer J Director A-Award A Phantom Stock Units 1,506 0.00 — 15,078 D ↗
2025-12-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 743,147 D ↗
2025-12-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 23 0.00 — 742,986 D ↗
2025-11-28 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 23 0.00 — 743,115 D ↗
2025-11-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 743,548 D ↗
2025-10-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 731,108 D ↗
2025-10-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 25 0.00 — 731,111 D ↗
2025-10-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 83 0.00 — 731,058 D ↗
2025-09-30 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,472 0.00 — 23,445 D ↗
2025-09-30 SMITH JAMES C Director A-Award A Phantom Stock Units 1,766 0.00 — 161,563 D ↗
2025-09-30 Quincey James Director A-Award A Phantom Stock Units 1,521 0.00 — 71,917 D ↗
2025-09-30 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 1,962 0.00 — 178,125 D ↗
2025-09-30 Echevarria Joseph Director A-Award A Phantom Stock Units 1,815 0.00 — 144,990 D ↗
2025-09-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 730,773 D ↗
2025-09-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 25 0.00 — 730,907 D ↗
2025-08-29 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 730,806 D ↗
2025-08-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 730,477 D ↗
2025-07-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 26 0.00 — 731,620 D ↗
2025-07-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 718,359 D ↗
2025-07-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 80 0.00 — 718,104 D ↗
2025-06-30 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,547 0.00 — 21,601 D ↗
2025-06-30 SMITH JAMES C Director A-Award A Phantom Stock Units 1,856 0.00 — 157,093 D ↗
2025-06-30 Quincey James Director A-Award A Phantom Stock Units 1,599 0.00 — 69,205 D ↗
2025-06-30 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 2,063 0.00 — 173,182 D ↗
2025-06-30 Echevarria Joseph Director A-Award A Phantom Stock Units 1,908 0.00 — 140,751 D ↗
2025-06-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 25 0.00 — 718,220 D ↗
2025-06-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 718,048 D ↗
2025-05-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 26 0.00 — 718,866 D ↗
2025-05-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 27 0.00 — 719,518 D ↗
2025-04-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 25 0.00 — 705,968 D ↗
2025-04-24 Taraporevala Cyrus Director A-Award A Phantom Stock Units 8,999 0.00 — 19,709 D ↗
2025-04-24 SMITH JAMES C Director A-Award A Phantom Stock Units 8,999 0.00 — 152,563 D ↗
2025-04-24 Quincey James Director A-Award A Phantom Stock Units 8,999 0.00 — 66,442 D ↗
2025-04-24 NORA JOHNSON SUZANNE M Director A-Award A Phantom Stock Units 8,999 0.00 — 109,296 D ↗
2025-04-24 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 8,999 0.00 — 168,172 D ↗
2025-04-24 LITTMAN DAN R. Director A-Award A Phantom Stock Units 8,999 0.00 — 62,510 D ↗
2025-04-24 Hockfield Susan Director A-Award A Phantom Stock Units 8,999 0.00 — 42,181 D ↗
2025-04-24 Gottlieb Scott Director A-Award A Phantom Stock Units 8,999 0.00 — 46,115 D ↗
2025-04-24 Echevarria Joseph Director A-Award A Phantom Stock Units 8,999 0.00 — 136,452 D ↗
2025-04-24 Desmond-Hellmann Susan Director A-Award A Phantom Stock Units 8,999 0.00 — 37,355 D ↗
2025-04-24 Buckley Mortimer J Director A-Award A Phantom Stock Units 8,999 0.00 — 12,893 D ↗
2025-04-24 BLAYLOCK RONALD E Director A-Award A Phantom Stock Units 8,999 0.00 — 71,374 D ↗
2025-04-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 45 0.00 — 707,396 D ↗
2025-04-10 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 1,484 0.00 — 707,507 D ↗
2025-03-31 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,480 0.00 — 10,710 D ↗
2025-03-31 SMITH JAMES C Director A-Award A Phantom Stock Units 1,776 0.00 — 143,564 D ↗
2025-03-31 Quincey James Director A-Award A Phantom Stock Units 1,529 0.00 — 57,443 D ↗
2025-03-31 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 1,973 0.00 — 159,173 D ↗
2025-03-31 Echevarria Joseph Director A-Award A Phantom Stock Units 1,825 0.00 — 127,453 D ↗
2025-03-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 24 0.00 — 705,510 D ↗
2025-03-14 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 1,905 0.00 — 705,449 D ↗
2025-03-04 de Germay Alexandre Officer A-Award A Stock Appreciation Rights 371,824 25.75 9.57M 371,824 D ↗
2025-03-04 SUSMAN SALLY Officer A-Award A Stock Appreciation Rights 156,992 25.75 4.04M 156,992 D ↗
2025-03-04 SAHNI PAYAL Officer A-Award A Stock Appreciation Rights 206,569 25.75 5.32M 206,569 D ↗
2025-03-04 McDermott Michael Officer A-Award A Stock Appreciation Rights 289,196 25.75 7.45M 289,196 D ↗
2025-03-04 MALIK AAMIR Officer A-Award A Stock Appreciation Rights 371,824 25.75 9.57M 371,824 D ↗
2025-03-04 LANKLER DOUGLAS M Officer A-Award A Stock Appreciation Rights 371,824 25.75 9.57M 371,824 D ↗
2025-03-04 Fonseca Lidia Officer A-Award A Stock Appreciation Rights 156,992 25.75 4.04M 156,992 D ↗
2025-03-04 Denton David M Officer A-Award A Stock Appreciation Rights 413,138 25.75 10.64M 413,138 D ↗
2025-03-04 DAMICO JENNIFER B. Officer A-Award A Common Stock 5,583 0.00 — 14,350 D ↗
2025-03-04 Baum Andrew Officer A-Award A Stock Appreciation Rights 206,569 25.75 5.32M 206,569 D ↗
2025-03-04 BOURLA ALBERT Director / Officer A-Award A Stock Appreciation Rights 1,487,296 25.75 38.30M 1,487,296 D ↗
2025-03-04 BOSHOFF CHRISTOFFEL Officer A-Award A Stock Appreciation Rights 495,765 25.75 12.77M 495,765 D ↗
2025-02-27 SUSMAN SALLY Officer F-InKind D Common Stock 2,178 26.10 56.8K 248,688 D ↗
2025-02-27 SAHNI PAYAL Officer M-Exempt A Common Stock 19,054 31.31 596.6K 44,242 D ↗
2025-02-27 McDermott Michael Officer M-Exempt A Common Stock 48,419 31.31 1.52M 122,413 D ↗
2025-02-27 LANKLER DOUGLAS M Officer M-Exempt D Stock Appreciation Rights 156,914 31.31 4.91M 0 D ↗
2025-02-27 Fonseca Lidia Officer M-Exempt D Stock Appreciation Rights 72,629 31.31 2.27M 0 D ↗
2025-02-27 DAMICO JENNIFER B. Officer F-InKind D Common Stock 749 26.10 19.5K 29,761 D ↗
2025-02-27 BOURLA ALBERT Director / Officer M-Exempt D Stock Appreciation Rights 582,823 31.31 18.25M 0 D ↗
2025-02-27 BOSHOFF CHRISTOFFEL Officer A-Award A Common Stock 17,450 0.00 — 172,147 D ↗
2025-02-26 McDermott Michael Officer F-InKind D Common Stock 3,220 26.42 85.1K 73,994 D ↗
2025-02-26 BOSHOFF CHRISTOFFEL Officer A-Award A Common Stock 9,687 0.00 — 159,972 D ↗
2025-02-24 DAMICO JENNIFER B. Officer F-InKind D Common Stock 377 26.65 10.0K 8,647 D ↗
2025-02-24 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 403 26.65 10.7K 149,882 D ↗
2025-02-23 DAMICO JENNIFER B. Officer F-InKind D Common Stock 390 26.30 10.3K 9,024 D ↗
2025-02-23 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 662 26.30 17.4K 150,285 D ↗
2025-02-22 SUSMAN SALLY Officer M-Exempt D Stock Appreciation Rights 63,573 30.17 1.92M 0 D ↗
2025-02-22 SAHNI PAYAL Officer — D Stock Appreciation Rights 12,079 35.74 431.7K 0 — ↗
2025-02-22 ROGERS DAWN Officer — D Stock Appreciation Rights 14,344 35.74 512.7K 0 — ↗
2025-02-22 McDermott Michael Officer — D Stock Appreciation Rights 11,125 30.17 335.6K 0 — ↗
2025-02-22 LANKLER DOUGLAS M Officer M-Exempt A Common Stock 85,824 30.17 2.59M 232,775 D ↗
2025-02-22 GOETTLER MICHAEL Officer — D Stock Appreciation Rights 15,099 35.74 539.6K 0 — ↗
2025-02-22 DAMICO JENNIFER B. Officer — D Stock Appreciation Rights 8,304 35.74 296.8K 0 — ↗
2025-02-22 Carapezzi William R JR Officer — D Stock Appreciation Rights 18,119 35.74 647.6K 0 — ↗
2025-02-22 BOURLA ALBERT Director / Officer F-InKind D Common Stock 8,835 26.30 232.4K 561,601 D ↗
2025-02-22 BOSHOFF CHRISTOFFEL Officer M-Exempt A Common Stock 8,741 30.17 263.7K 159,085 D ↗
2025-02-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 625 0.00 — 702,791 D ↗
2025-02-13 BLAYLOCK RONALD E Director P-Purchase A Common Stock 19,457 25.65 499.1K 27,707 D ↗
2025-01-31 BOSHOFF CHRISTOFFEL Officer F-InKind D Common Stock 12,038 26.52 319.2K 150,344 D ↗
2025-01-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 75 0.00 — 690,650 D ↗
2024-12-31 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,413 0.00 — 9,084 D ↗
2024-12-31 SMITH JAMES C Director A-Award A Phantom Stock Units 1,696 0.00 — 139,544 D ↗
2024-12-31 Quincey James Director A-Award A Phantom Stock Units 1,461 0.00 — 55,029 D ↗
2024-12-31 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 1,885 0.00 — 154,711 D ↗
2024-12-31 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 7 0.00 — 9,379 D ↗
2024-12-31 Echevarria Joseph Director A-Award A Phantom Stock Units 1,743 0.00 — 123,639 D ↗
2024-12-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 20 0.00 — 690,585 D ↗
2024-12-13 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 7 0.00 — 9,373 D ↗
2024-12-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 21 0.00 — 690,626 D ↗
2024-11-29 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 7 0.00 — 9,363 D ↗
2024-11-29 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 20 0.00 — 690,388 D ↗
2024-11-15 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 8 0.00 — 9,365 D ↗
2024-11-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 21 0.00 — 691,116 D ↗
2024-10-31 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 7 0.00 — 9,197 D ↗
2024-10-31 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 19 0.00 — 679,129 D ↗
2024-10-30 Gottlieb Scott Director P-Purchase A Common Stock 1,000 28.24 28.2K 10,000 D ↗
2024-10-15 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 6 0.00 — 9,189 D ↗
2024-10-15 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 18 0.00 — 679,044 D ↗
2024-10-10 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 29 0.00 — 9,183 D ↗
2024-10-10 Buckley Mortimer J Director — — — 0 0.00 — 0 — ↗
2024-10-10 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 69 0.00 — 679,059 D ↗
2024-09-30 Taraporevala Cyrus Director A-Award A Phantom Stock Units 1,296 0.00 — 7,547 D ↗
2024-09-30 SMITH JAMES C Director A-Award A Phantom Stock Units 1,555 0.00 — 135,661 D ↗
2024-09-30 Quincey James Director A-Award A Phantom Stock Units 1,339 0.00 — 52,711 D ↗
2024-09-30 NARAYEN SHANTANU Director A-Award A Phantom Stock Units 1,728 0.00 — 150,380 D ↗
2024-09-30 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 6 0.00 — 9,155 D ↗
2024-09-30 Echevarria Joseph Director A-Award A Phantom Stock Units 1,598 0.00 — 119,945 D ↗
2024-09-30 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 18 0.00 — 679,014 D ↗
2024-09-13 JOHNSON RADY A Officer A-Award A Phantom Stock Units SSP 6 0.00 — 9,148 — ↗
2024-09-13 BOURLA ALBERT Director / Officer A-Award A Phantom Stock Units SSP 18 0.00 — 678,971 — ↗
2024-09-12 SUSMAN SALLY Officer D-Return D Stock Appreciation Rights 43,624 42.30 1.85M 0 — ↗
2024-09-12 SAHNI PAYAL Officer A-Award A Stock Appreciation Rights 42,265 45.96 1.94M 42,265 — ↗
2024-09-12 McDermott Michael Officer A-Award A Stock Appreciation Rights 34,234 45.96 1.57M 34,234 — ↗
2024-09-12 MALIK AAMIR Officer D-Return D Stock Appreciation Rights 103,320 42.30 4.37M 0 — ↗

Executive team

Top executives
EBIT / Employee
125.8K
Shares Outstanding
5.69B

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 A. Bourla Chairman and Chief Executive Officer 1.80M — 9.44M 9.00M 5.40M 1.94M 27.59M 66.85% ↗
2 2025 C. Boshoff Chief Scientific Officer and President, Research & Development 1.40M — 1.81M 3.00M 3.15M 648.0K 10.01M 48.05% ↗
3 2025 D. Denton Chief Financial Officer, EVP 1.39M — 2.37M 2.50M 2.80M 613.8K 9.67M 50.33% ↗
4 2025 A. Malik Chief U.S. Commercial Officer, EVP 1.39M — 2.28M 2.25M 2.90M 611.2K 9.43M 48.05% ↗
5 2025 D. Lankler Chief Legal Officer, EVP 1.41M — 1.98M 2.25M 2.68M 793.6K 9.11M 46.41% ↗
6 2024 A. Bourla Chairman and Chief Executive Officer 1.80M — 4.84M 9.99M 7.02M 996.1K 24.65M 60.18% ↗
7 2024 M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development 1.65M — 1.57M 3.32M 2.90M 309.6K 9.74M 50.13% ↗
8 2024 A. Malik Chief U.S. Commercial Officer, EVP 1.34M — 1.13M 2.48M 3.09M 253.2K 8.29M 43.44% ↗
9 2024 D. Denton Chief Financial Officer, EVP 1.35M — 1.13M 2.45M 2.96M 236.9K 8.12M 44.03% ↗
10 2024 C. Boshoff Chief Scientific Officer and President, Research & Development 1.20M — 896.3K 2.25M 2.88M 627.8K 7.85M 40.06% ↗
11 2024 D. Lankler Chief Legal Officer, EVP 1.24M — 913.3K 1.94M 2.46M 256.0K 6.81M 41.81% ↗
12 2023 A. Bourla Chairman and Chief Executive Officer 1.79M — 8.75M 8.76M — 2.27M 21.56M 81.19% ↗
13 2023 M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development 1.60M — 3.12M 2.92M — 1.23M 8.86M 68.13% ↗
14 2023 A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.34M — 2.34M 2.19M — 826.4K 6.69M 67.63% ↗
15 2023 W. Pao Former Chief Development Officer, EVP 772.5K 691.9K 577.9K 1.70M — 2.51M 6.25M 36.50% ↗
16 2023 D. Lankler Chief Legal Officer, EVP 1.20M — 1.82M 1.70M — 758.6K 5.48M 64.28% ↗
17 2023 D. Lankler General Counsel, EVP 1.20M — 1.82M 1.70M — 758.6K 5.48M 64.28% ↗
18 2023 A. Malik Chief U.S. Commercial Officer, EVP 1.29M — 1.34M 2.19M — 599.3K 5.42M 65.06% ↗
19 2023 D. Denton Chief Financial Officer, EVP 1.30M — 1.34M 2.19M — 451.2K 5.28M 66.89% ↗
20 2022 A. Bourla Chairman and Chief Executive Officer 1.74M — 9.30M 9.53M 7.65M 4.81M 33.02M 57.01% ↗
21 2022 D. Denton Chief Financial Officer, EVP 833.3K 5.00M 4.00M 2.25M 1.84M 10.52M 24.44M 25.57% ↗
22 2022 W. Pao Chief Development Officer, EVP 937.5K 5.00M 6.00M — 1.57M 3.76M 17.26M 34.75% ↗
23 2022 W. Pao Former Chief Development Officer, EVP 937.5K 5.00M 6.00M — 1.57M 3.76M 17.26M 34.75% ↗
24 2022 M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical 1.54M — 3.47M 2.93M 3.53M 749.8K 12.22M 52.40% ↗
25 2022 M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development 1.54M — 3.47M 2.93M 3.53M 749.8K 12.22M 52.40% ↗
26 2022 F. D’Amelio Former Chief Financial Officer, EVP 1.45M — 3.70M 2.93M 1.45M 1.01M 10.54M 62.96% ↗
27 2022 A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.28M — 2.66M 2.20M 2.94M 673.4K 9.75M 49.86% ↗
28 2022 A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.28M — 2.66M 2.20M 2.94M 673.4K 9.75M 49.86% ↗
29 2022 D. Lankler General Counsel, EVP 1.14M — 2.16M 1.71M 2.26M 547.2K 7.83M 49.45% ↗
30 2021 A. Bourla Chairman and Chief Executive Officer 1.69M — 6.18M 7.05M 8.00M 1.43M 24.35M 54.33% ↗
31 2021 F. D’Amelio Former Chief Financial Officer, EVP 1.57M — 2.84M 3.02M 2.93M 679.1K 11.04M 53.11% ↗
32 2021 F. D’Amelio Chief Financial Officer, EVP, Global Supply 1.57M — 2.84M 3.02M 2.93M 679.1K 11.04M 53.11% ↗
33 2021 M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development 1.48M — 2.53M 3.02M 3.25M 633.1K 10.91M 50.88% ↗
34 2021 M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical 1.48M — 2.53M 3.02M 3.25M 633.1K 10.91M 50.88% ↗
35 2021 M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical 1.48M — 2.53M 3.02M 3.25M 633.1K 10.91M 50.88% ↗
36 2021 A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.22M — 1.98M 2.27M 2.98M 586.2K 9.03M 46.96% ↗
37 2021 A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.22M — 1.98M 2.27M 2.98M 586.2K 9.03M 46.96% ↗
38 2021 A. Hwang Group President, Pfizer Biopharmaceuticals Group 1.22M — 1.98M 2.27M 2.98M 586.2K 9.03M 46.96% ↗
39 2021 J. Young Former Group President, Chief Business Officer 1.32M — 1.89M 2.01M 2.39M 714.1K 8.33M 46.90% ↗
40 2021 D. Lankler General Counsel, EVP 1.10M — 1.59M 1.76M 2.19M 484.4K 7.13M 47.00% ↗
41 2020 A. Bourla Chairman and Chief Executive Officer 1.65M — 4.90M 6.78M 5.49M 2.21M 21.03M 55.53% ↗
42 2020 F. D’Amelio Chief Financial Officer and EVP, Global Supply 1.53M — 2.41M 3.13M 2.47M 1.84M 11.38M 48.67% ↗
43 2020 F. D’Amelio Former Chief Financial Officer, EVP 1.53M — 2.41M 3.13M 2.47M 1.84M 11.38M 48.67% ↗
44 2020 F. D’Amelio Chief Financial Officer, EVP, Global Supply 1.53M — 2.41M 3.13M 2.47M 1.84M 11.38M 48.67% ↗
45 2020 M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical 1.43M — 2.11M 2.61M 2.60M 1.40M 10.15M 46.50% ↗
46 2020 M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical 1.43M — 2.11M 2.61M 2.60M 1.40M 10.15M 46.50% ↗
47 2020 J. Young Former Group President, Chief Business Officer 1.29M — 1.81M 2.09M 1.80M 2.00M 8.99M 43.41% ↗
48 2020 J. Young Chief Business Officer, Group President 1.29M — 1.81M 2.09M 1.80M 2.00M 8.99M 43.41% ↗
49 2020 A. Hwang Group President, Pfizer Biopharmaceuticals Group 1.14M — 1.42M 2.09M 2.39M 846.0K 7.88M 44.49% ↗
50 2020 A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business 1.14M — 1.42M 2.09M 2.39M 846.0K 7.88M 44.49% ↗
51 2019 A. Bourla Chief Executive Officer 1.60M — 4.29M 6.08M 3.63M 2.33M 17.93M 57.82% ↗
52 2019 A. Bourla Chairman and Chief Executive Officer 1.60M — 4.29M 6.08M 3.63M 2.33M 17.93M 57.82% ↗
53 2019 I. Read Executive Chairman 1.20M — 6.74M 4.05M 2.52M 1.77M 16.29M 66.27% ↗
54 2019 F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply 1.50M — 2.58M 3.04M 1.82M 2.14M 11.08M 50.74% ↗
55 2019 F. D’Amelio Chief Financial Officer, EVP, Global Supply 1.50M — 2.58M 3.04M 1.82M 2.14M 11.08M 50.74% ↗
56 2019 F. D’Amelio Chief Financial Officer and EVP, Global Supply 1.50M — 2.58M 3.04M 1.82M 2.14M 11.08M 50.74% ↗
57 2019 M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical 1.40M — 2.41M 2.53M 1.82M 1.43M 9.60M 51.53% ↗
58 2019 J. Young Chief Business Officer, Group President 1.25M — 2.25M 2.03M 1.68M 1.77M 8.96M 47.68% ↗
59 2019 J. Young Former Group President, Chief Business Officer 1.25M — 2.25M 2.03M 1.68M 1.77M 8.96M 47.68% ↗
60 2018 I. Read Executive Chairman 1.99M — 7.03M 6.85M 3.00M 671.8K 19.55M 71.03% ↗
61 2018 I. Read Chairman and Chief Executive Officer 1.99M — 7.03M 6.85M 3.00M 671.8K 19.55M 71.03% ↗
62 2018 A. Bourla Chairman and Chief Executive Officer 1.40M — 2.59M 3.95M 1.53M 375.1K 9.85M 66.43% ↗
63 2018 A. Bourla Chief Executive Officer 1.40M — 2.59M 3.95M 1.53M 375.1K 9.85M 66.43% ↗
64 2018 A. Bourla Chief Operating Officer 1.40M — 2.59M 3.95M 1.53M 375.1K 9.85M 66.43% ↗
65 2018 F. D’Amelio Chief Financial Officer and EVP, Global Supply 1.41M — 2.01M 2.11M 1.31M 299.8K 7.14M 57.73% ↗
66 2018 F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply 1.41M — 2.01M 2.11M 1.31M 299.8K 7.14M 57.73% ↗
67 2018 J. Young Chief Business Officer, Group President 1.21M — 2.01M 2.11M 1.39M 408.4K 7.12M 57.88% ↗
68 2018 J. Young Group President, Pfizer Innovative Health 1.21M — 2.01M 2.11M 1.39M 408.4K 7.12M 57.88% ↗
69 2018 M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical 1.31M — 2.01M 2.11M 1.33M 315.9K 7.07M 58.30% ↗
70 2018 M. Dolsten President, Worldwide Research and Development 1.31M — 2.01M 2.11M 1.33M 315.9K 7.07M 58.30% ↗
71 2017 I. Read Chairman and Chief Executive Officer 1.96M — 6.63M 14.50M 2.60M 2.22M 27.91M 75.72% ↗
72 2017 I. Read Executive Chairman 1.96M — 6.63M 14.50M 2.60M 2.22M 27.91M 75.72% ↗
73 2017 J. Young Chief Business Officer, Group President 1.17M — 3.88M 3.80M 1.02M 1.64M 11.51M 66.78% ↗
74 2017 J. Young Group President, Pfizer Essential Health 1.17M — 3.88M 3.80M 1.02M 1.64M 11.51M 66.78% ↗
75 2017 J. Young Group President, Pfizer Innovative Health 1.17M — 3.88M 3.80M 1.02M 1.64M 11.51M 66.78% ↗
76 2017 A. Bourla Chief Executive Officer 1.17M — 1.65M 1.80M 1.26M 2.95M 8.84M 39.07% ↗
77 2017 A. Bourla Chief Operating Officer 1.17M — 1.65M 1.80M 1.26M 2.95M 8.84M 39.07% ↗
78 2017 A. Bourla Group President, Pfizer Innovative Health 1.17M — 1.65M 1.80M 1.26M 2.95M 8.84M 39.07% ↗
79 2017 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.36M — 1.88M 1.80M 1.12M 2.14M 8.30M 44.39% ↗
80 2017 F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply 1.36M — 1.88M 1.80M 1.12M 2.14M 8.30M 44.39% ↗
81 2017 M. Dolsten President, Worldwide Research and Development 1.27M — 1.88M 1.80M 1.15M 1.57M 7.67M 48.02% ↗
82 2017 M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical 1.27M — 1.88M 1.80M 1.15M 1.57M 7.67M 48.02% ↗
83 2016 I. Read Chairman and Chief Executive Officer 1.91M — 3.98M 6.63M 4.00M 803.2K 17.32M 61.27% ↗
84 2016 G. Germano Former Group President, Global Innovative Pharma Business 489.6K — 533.7K — 486.1K 11.71M 13.22M 4.04% ↗
85 2016 A. Bourla Group President, Pfizer Innovative Health 1.12M — 936.9K 1.84M 1.79M 3.19M 8.87M 31.26% ↗
86 2016 A. Bourla Chief Operating Officer 1.12M — 936.9K 1.84M 1.79M 3.19M 8.87M 31.26% ↗
87 2016 M. Dolsten President, Worldwide Research and Development 1.24M — 1.14M 1.84M 1.74M 2.27M 8.23M 36.22% ↗
88 2016 F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply 1.32M — 1.14M 1.84M 1.74M 1.65M 7.69M 38.73% ↗
89 2016 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.32M — 1.14M 1.84M 1.74M 1.65M 7.69M 38.73% ↗
90 2016 J. Young Group President, Pfizer Essential Health 1.13M — 1.14M 1.84M 1.79M 1.50M 7.40M 40.29% ↗
91 2016 J. Young Group President, Pfizer Innovative Health 1.13M — 1.14M 1.84M 1.79M 1.50M 7.40M 40.29% ↗
92 2015 I. Read Chairman and Chief Executive Officer 1.86M — 2.01M 5.84M 4.30M 3.97M 17.99M 43.67% ↗
93 2015 G. Germano Group President, Global Innovative Pharma Business 1.17M — 603.5K 1.75M 1.85M 1.41M 6.78M 34.74% ↗
94 2015 G. Germano Former Group President, Global Innovative Pharma Business 1.17M — 603.5K 1.75M 1.85M 1.41M 6.78M 34.74% ↗
95 2015 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.29M — 603.5K 1.75M 2.34M 679.0K 6.67M 35.33% ↗
96 2015 M. Dolsten President, Worldwide Research and Development 1.21M — 603.5K 1.75M 1.85M 644.0K 6.06M 38.90% ↗
97 2015 J. Young Group President, Pfizer Essential Health 1.09M — 603.5K 1.75M 2.10M 377.5K 5.92M 39.81% ↗
98 2015 J. Young Group President, Global Established Pharma Business 1.09M — 603.5K 1.75M 2.10M 377.5K 5.92M 39.81% ↗
99 2014 I. Read Chairman and Chief Executive Officer 1.82M — — — — 391.8K 23.28M 0.00% ↗
100 2014 I. Read Chairman and Chief Executive Officer 1.82M — 6.45M 6.36M 3.00M 5.66M 23.28M 55.02% ↗
101 2014 G. Germano Group President, Global Innovative 1.15M — — — — 630.6K 9.56M 0.00% ↗
102 2014 G. Germano Former Group President, Global Innovative Pharma Business 1.15M — 1.81M 1.79M 1.36M 3.45M 9.56M 37.70% ↗
103 2014 G. Germano Group President, Global Innovative Pharma Business 1.15M — 1.81M 1.79M 1.36M 3.45M 9.56M 37.70% ↗
104 2014 F. D’Amelio EVP, Business Operations 1.27M — — — — 217.5K 8.48M 0.00% ↗
105 2014 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.27M — 2.14M 2.11M 1.30M 1.66M 8.48M 50.14% ↗
106 2014 M. Dolsten President, Worldwide Research and Development 1.18M — 1.86M 1.84M 1.30M 1.09M 7.28M 50.90% ↗
107 2014 M. Dolsten President, Worldwide Research and 1.18M — — — — 156.2K 7.28M 0.00% ↗
108 2014 J. Young Group President, Global Established Pharma Business 1.04M — 1.81M 1.79M 1.26M 1.35M 7.25M 49.69% ↗
109 2014 J. Young Group President, Pfizer Essential Health 1.04M — 1.81M 1.79M 1.26M 1.35M 7.25M 49.69% ↗
110 2014 J. Young Group President, 1.04M — — — — 326.5K 7.25M 0.00% ↗
111 2013 I. Read Chairman and Chief Executive Officer 1.78M — 6.02M 6.07M 3.40M 1.69M 18.95M 63.77% ↗
112 2013 I. Read Chairman and Chief Executive Officer 1.78M — — — — 476.3K 18.95M 0.00% ↗
113 2013 O. Brandicourt 812.1K — — — — 3.48M 8.10M 0.00% ↗
114 2013 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.24M — 1.94M 1.95M 1.65M 339.4K 7.12M 54.62% ↗
115 2013 F. D’Amelio EVP, Business Operations 1.24M — — — — 235.7K 7.12M 0.00% ↗
116 2013 M. Dolsten President, Worldwide Research and Development 1.15M — 1.84M 1.85M 1.34M 278.3K 6.45M 57.12% ↗
117 2013 M. Dolsten President, Worldwide Research and 1.15M — — — — 164.5K 6.45M 0.00% ↗
118 2013 J. Young Group President, Global Established Pharma Business 810.1K — 1.12M 1.13M 1.08M 1.16M 5.30M 42.53% ↗
119 2013 J. Young Group President, 810.1K — — — — 287.6K 5.30M 0.00% ↗
120 2013 G. Germano Group President, Global Innovative 926.3K — — — — 173.2K 5.25M 0.00% ↗
121 2013 G. Germano Group President, Global Innovative Pharma Business 926.3K — 1.53M 1.54M 1.08M 180.9K 5.25M 58.47% ↗
122 2013 G. Germano President and General Manager, 926.3K — — — — 173.2K 5.25M 0.00% ↗
123 2013 A. W. Schulman Former EVP and General Counsel; Business 952.8K — — — — 110.5K 5.12M 0.00% ↗
124 2012 I. Read Chairman and Chief Executive Officer 1.74M — — — — 409.9K 25.63M 0.00% ↗
125 2012 F. D’Amelio EVP, Business Operations 1.22M — — — — 173.2K 7.39M 0.00% ↗
126 2012 G. Germano President and General Manager, 893.8K — — — — 121.7K 7.31M 0.00% ↗
127 2012 G. Germano Group President, Global Innovative 893.8K — — — — 121.7K 7.31M 0.00% ↗
128 2012 M. Dolsten President, Worldwide Research and 1.12M — — — — 96.8K 6.84M 0.00% ↗
129 2012 A. W. Schulman EVP and General 918.8K — 1.39M 1.40M 1.41M 87.4K 5.57M 50.01% ↗
130 2012 A. W. Schulman Former EVP and General Counsel; Business 918.8K — — — — 87.4K 5.57M 0.00% ↗
131 2011 I. Read Chairman and Chief Executive Officer* 1.70M — 5.68M 6.92M 3.50M 319.3K 25.01M 50.38% ↗
132 2011 I. Read Chairman and Chief Executive Officer 1.70M — — — — 319.3K 25.01M 0.00% ↗
133 2011 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.20M — 2.05M 1.83M 1.44M 187.4K 7.69M 50.43% ↗
134 2011 F. D’Amelio EVP, Business Operations 1.20M — — — — 187.4K 7.69M 0.00% ↗
135 2011 M. Dolsten President, Worldwide Research and 1.10M — — — — 90.8K 6.98M 0.00% ↗
136 2011 M. Dolsten President, Worldwide Research and Development 1.10M — 2.05M 1.83M 1.49M 90.8K 6.98M 55.59% ↗
137 2011 G. Germano President and General Manager, 875.0K — — — — 50.2K 6.40M 0.00% ↗
138 2011 D. Simmons President and GM, Emerging Markets and Established Products 850.0K — 1.59M 1.43M 1.14M 132.2K 5.98M 50.47% ↗
139 2011 A. W. Schulman Former EVP and General Counsel; Business 900.0K — — — — 94.2K 5.76M 0.00% ↗
140 2011 A. W. Schulman EVP and General 900.0K — 1.71M 1.53M 1.19M 94.2K 5.76M 56.07% ↗
141 2011 A. W. Schulman EVP, General Counsel, and President GM, Nutrition 900.0K — 1.71M 1.53M 1.19M 94.2K 5.76M 56.07% ↗
142 2010 I. Read Chairman and Chief Executive Officer 1.20M — 2.67M 837.6K 1.50M 209.7K 17.40M 20.18% ↗
143 2010 I. Read Chairman and Chief Executive Officer* 1.20M — 2.67M 837.6K 1.50M 209.7K 17.40M 20.18% ↗
144 2010 F. D’Amelio EVP, Business Operations 1.09M — 2.67M 837.6K 1.18M 193.8K 6.50M 54.01% ↗
145 2010 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.09M — 2.67M 837.6K 1.18M 193.8K 6.50M 54.01% ↗
146 2010 M. Dolsten President, Worldwide Research and Development 900.0K 1.05M 1.99M 622.2K 1.00M 61.0K 5.90M 44.18% ↗
147 2010 M. Dolsten President, Worldwide Research and 900.0K 1.05M 1.99M 622.2K 1.00M 61.0K 5.90M 44.18% ↗
148 2010 G. Germano President and General Manager, 818.0K 750.0K 1.13M 354.2K 930.0K 25.6K 4.81M 30.85% ↗
149 2010 2010 SUMMARY COMPENSATION TABLE — — — — — — — — ↗
150 2009 I. Read Chairman and Chief Executive Officer* 1.14M 500.0K 2.85M 1.15M 1.66M 226.6K 9.45M 42.43% ↗
151 2009 F. D’Amelio EVP, Business Operations and Chief Financial Officer 1.06M 600.0K 2.90M 1.20M 1.42M 205.3K 7.86M 52.28% ↗
152 2009 F. Lewis-Hall Chief Medical Officer 503.0K 1.63M 1.00M — — — 3.13M 31.95% ↗
153 2009 2009 Summary Compensation Table Name and Principal Position (a) 2.0K 2.0K 2.0K — — — 6.0K 33.33% ↗
154 2008 C. Goodman President, Biotherapeutics Bioinnovation Center 736.3K 1.70M 778.9K — — — 3.22M 24.23% ↗
155 2008 2008 Summary Compensation Table Name and Principal Position (a) 2.0K 2.0K — — — — 4.0K 0.00% ↗
156 2007 J. Kindler Chairman and 1.46M 3.10M 1.16M — — — 5.73M 20.31% ↗
157 2007 F. D’Amelio Chief Financial 320.6K 4.04M 907.7K — — — 5.27M 17.23% ↗
158 2007 I. Read President, Worldwide 944.1K 990.0K 190.1K — — — 2.12M 8.95% ↗
159 2007 D. Shedlarz Former Vice Chairman 1.06M 951.2K 62.3K — — — 2.07M 3.01% ↗
160 2007 J. LaMattina Former President, 911.3K 683.5K 247.4K — — — 1.84M 13.43% ↗
161 2007 M. Mackay President, 702.2K 645.0K 166.3K — — — 1.51M 10.99% ↗
162 2007 A. Levin Former 687.9K 486.8K 37.0K — — — 1.21M 3.05% ↗
163 2006 J. Kindler Chairman and 1.10M 3.30M 2.74M — — — 7.14M 38.32% ↗
164 2006 D. Shedlarz Former Vice Chairman 1.01M 1.26M 3.18M — — — 5.45M 58.34% ↗
165 2006 J. LaMattina Former President, 873.3K 718.3K 2.45M — — — 4.04M 60.63% ↗
166 2006 A. Levin Former 784.6K 580.6K 2.03M — — — 3.39M 59.75% ↗
167 2006 I. Read President, Worldwide 813.5K 667.2K 1.65M — — — 3.13M 52.73% ↗
168 2006 M. Mackay President, — — — — — — — — ↗
169 2006 F. D’Amelio Chief Financial — — — — — — — — ↗
170 2005 Dr. McKinnell Chairman and CEO 2.27M 3.70M — — — 281.6K 6.25M 0.00% ↗
171 2005 Vice Chairman and President, Pfizer Human Health 1.18M 1.54M — — — 110.3K 2.82M 0.00% ↗
172 2005 Mr. Shedlarz Vice Chairman 983.1K 1.09M — — — 89.5K 2.16M 0.00% ↗
173 2005 Mr. Kindler Vice Chairman and General Counsel 902.2K 1.00M — — — 79.7K 1.98M 0.00% ↗
174 2005 Senior V.P.; President, Pfizer Global Research and Development 837.5K 787.3K — — — 69.4K 1.69M 0.00% ↗
175 2004 Dr. McKinnell Chairman and CEO 2.22M 3.99M 4.29M — — 307.5K 10.81M 39.70% ↗
176 2004 Vice Chairman and President, Pfizer Human Health 1.16M 1.27M 2.33M — — 117.8K 4.88M 47.70% ↗
177 2004 Mr. Shedlarz Vice Chairman 966.5K 1.01M 1.87M — — 90.4K 3.94M 47.60% ↗
178 2004 Mr. Kindler Vice Chairman and General Counsel 887.3K 869.6K 792.6K — — 80.5K 2.63M 30.14% ↗
179 2004 Senior V.P.; President, Pfizer Global Research and Development 820.0K 705.2K 1.02M — — 63.8K 2.61M 39.19% ↗
180 2003 Dr. McKinnell Chairman and CEO 2.04M 4.61M — — — 249.4K 6.90M 0.00% ↗
181 2003 Vice Chairman and President, Pfizer Human Health 1.09M 1.43M 326.8K — — 103.6K 2.95M 11.07% ↗
182 2003 Executive V.P.; President, Pfizer Global Pharmaceuticals 1.09M 1.43M 326.8K 275.0K — 90.9K 2.94M 20.48% ↗
183 2003 Mr. Kindler Senior V.P. and General Counsel 827.9K 901.5K 249.0K 200.0K — 621.9K 2.60M 17.27% ↗
184 2003 Mr. Shedlarz Vice Chairman 889.1K 1.04M 260.9K — — 79.9K 2.27M 11.48% ↗
185 2003 Mr. Shedlarz Executive V.P. and CFO 889.1K 1.04M 260.9K 225.0K — 70.4K 2.26M 21.47% ↗
186 2003 Mr. Kindler Vice Chairman and General Counsel 827.9K 901.5K 249.0K — — 69.0K 2.05M 12.16% ↗
187 2003 Dr. Corr Senior V.P., Science and Technology 806.0K 815.0K 242.4K 110.0K — 114.6K 1.98M 17.82% ↗
188 2003 Senior V.P.; President, Pfizer Global Research and Development 677.3K 596.9K 199.3K — — 50.4K 1.52M 13.08% ↗
189 2002 Dr. McKinnell Chairman and CEO 1.81M 3.50M — — — 205.9K 5.52M 0.00% ↗
190 2002 Mr. Kindler Vice Chairman and General Counsel 725.0K 704.6K 798.0K — — 621.9K 2.85M 28.00% ↗
191 2002 Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals 984.1K 1.24M — 250.0K — 90.9K 2.32M 10.80% ↗
192 2002 Vice Chairman and President, Pfizer Human Health 984.1K 1.24M — — — 90.9K 2.32M 0.00% ↗
193 2002 Executive V.P.; President, Pfizer Global Pharmaceuticals 984.1K 1.24M — 250.0K — 63.4K 2.29M 10.93% ↗
194 2002 Mr. Kindler Senior V.P. and General Counsel 725.0K 704.6K 798.0K 150.0K — — 2.23M 42.56% ↗
195 2002 Mr. Shedlarz Vice Chairman 834.0K 886.9K — — — 70.4K 1.79M 0.00% ↗
196 2002 Mr. Shedlarz Executive V.P. and CFO 834.0K 886.9K — 200.0K — 59.9K 1.78M 11.23% ↗
197 2002 Senior V.P.; President, Pfizer Global Research and Development 630.8K 441.7K 508.5K — — 49.5K 1.63M 31.19% ↗
198 2002 Dr. Niblack Former Vice Chairman* 686.1K 708.5K — 275.0K — 78.3K 1.47M 18.67% ↗
199 2002 Dr. Corr Senior V.P., Science and Technology 705.7K 530.0K — 100.0K — 42.1K 1.28M 7.83% ↗
200 2001 Dr. McKinnell* Chairman and CEO 1.52M 2.78M — 800.0K — 117.7K 4.42M 18.12% ↗
201 2001 Dr. McKinnell Chairman and CEO 1.52M 2.78M — — — — 4.30M 0.00% ↗
202 2001 Mr. Steere Former Chairman** 808.0K 1.62M — — — 549.4K 2.97M 0.00% ↗
203 2001 Dr. Niblack Vice Chairman 944.6K 1.06M — 450.0K — 75.1K 2.08M 21.61% ↗
204 2001 Dr. Niblack Former Vice Chairman* 944.6K 1.06M — 450.0K — 75.1K 2.08M 21.61% ↗
205 2001 Executive V.P.; President, Pfizer Global Pharmaceuticals 854.6K 1.04M — 330.0K — 79.9K 1.98M 16.68% ↗
206 2001 Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals 854.6K 1.04M — 330.0K — 63.4K 1.96M 16.82% ↗
207 2001 Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals 854.6K 1.04M — 330.0K — 63.4K 1.96M 16.82% ↗
208 2001 Mr. Shedlarz Executive V.P. and CFO 772.8K 736.9K — — — 69.0K 1.58M 0.00% ↗
209 2001 Mr. Shedlarz Executive V.P. and CFO 772.8K 736.9K — 330.0K — 59.9K 1.57M 21.03% ↗
210 2001 C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel 679.5K 680.9K — 225.0K — 54.4K 1.41M 15.90% ↗
211 2001 Dr. Corr Senior V.P., Science and Technology 630.0K 530.0K — 250.0K — — 1.16M 21.55% ↗
212 2001 Mr. Kindler Senior V.P. and General Counsel — — — — — 89.4K 89.4K 0.00% ↗
213 2000 Mr. Steere Former Chairman** 1.62M 3.23M 2.69M — — 179.5K 7.72M 34.84% ↗
214 2000 Dr. McKinnell* Chairman and CEO 984.1K 1.43M 1.41M — — 83.1K 3.90M 36.10% ↗
215 2000 Dr. McKinnell Chairman and CEO 984.1K 1.43M 1.41M — — 83.1K 3.90M 36.10% ↗
216 2000 Dr. Niblack Vice Chairman 832.5K 932.4K 1.10M — — 69.1K 2.93M 37.43% ↗
217 2000 Dr. Niblack Former Vice Chairman* 832.5K 932.4K 1.10M 210.0K — 69.1K 2.93M 44.59% ↗
218 2000 Mr. Shedlarz Executive V.P. and CFO 695.1K 723.7K 763.6K — — 53.5K 2.24M 34.15% ↗
219 2000 Mr. Shedlarz Executive V.P. and CFO 695.1K 723.7K 763.6K — — 53.5K 2.24M 34.15% ↗
220 2000 Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals 698.8K 730.3K 688.3K 165.0K — 53.8K 2.17M 39.30% ↗
221 2000 Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals 698.8K 730.3K 688.3K 165.0K — 53.8K 2.17M 39.30% ↗
222 2000 C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel 651.5K 680.9K 645.3K 140.0K — 45.4K 2.02M 38.82% ↗
223 2000 Dr. Corr Senior V.P., Science and Technology 575.0K 530.0K — 346.8K — 28.2K 1.13M 30.60% ↗
224 2000 Mr. Kindler Senior V.P. and General Counsel — — — — — — — — ↗
225 1999 Mr. Steere Former Chairman** 1.44M 2.87M — — — 167.8K 4.48M 0.00% ↗
226 1999 Dr. McKinnell* Chairman and CEO 869.8K 1.09M 2.00M — — 76.8K 4.04M 49.55% ↗
227 1999 Dr. Niblack Vice Chairman 799.7K 895.7K 1.80M — — 66.4K 3.56M 50.58% ↗
228 1999 Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals 625.8K 645.5K 130.9K — — 45.3K 1.45M 9.04% ↗
229 1999 Mr. Shedlarz Executive V.P. and CFO 625.8K 642.6K 65.5K — — 47.6K 1.38M 4.74% ↗
230 1999 C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel 625.8K 654.0K — 225.5K — 43.3K 1.32M 17.04% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-03-12 DEFA14A ↗
2026-03-12 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-05 S-8 ↗
2026-05-05 8-K ↗
2026-05-05 10-Q ↗
2026-05-04 4 ↗
2026-04-27 8-K ↗
2026-04-27 4 ↗
2026-04-27 4 ↗
2026-04-27 4 ↗
2026-04-27 4 ↗
2026-04-27 4 ↗

Executive team

NameTitleCompensationGender
Albert Bourla Chairman of the Board & Chief Executive Officer 9M —
Chris Boshoff FMedSci Chief Scientific Officer and President of Research & Development 5M —
Aamir Malik Executive Vice President & Chief U.S. Commercial Officer 5M male
David Denton Executive Vice President & Chief Financial Officer 5M male
Douglas Lankler Executive Vice President & Chief Legal Officer 5M male
Dennis Hancock Executive VP & Chief Information Officer — male
Francesca DeMartino Chief Investor Relations Officer — female
Jennifer Damico Senior Vice President, Controller & Principal Accounting Officer — female
Lidia L. Fonseca Executive Vice President and Chief Digital & Technology Officer — female
Michael S. Vincent Senior Vice President and Chief Scientific Officer of Inflammation & Immunology — —
Payal Sahni Becher Chief People Experience Officer & Executive Vice President — female
ESG Rating
B+
DRUG MANUFACTURERS - GENERAL
2006
E (Environmental)
75.2 / 68.7
Company / Sector avg.
S (Social)
62.9 / 66.7
Company / Sector avg.
G (Governance)
68.3 / 67.9
Company / Sector avg.
ESG Total
68.8 / 67.7
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
Transaction Date Disclosed Senator State Owner Type Amount Link
2026-02-03 2026-03-26 Susan M. Collins ME Spouse Purchase $15,001 - $50,000 ↗
2025-06-03 2025-07-02 Ron Wyden OR Spouse Sale (Full) $1,001 - $15,000 ↗
2025-06-03 2025-07-03 Ron Wyden OR Spouse Sale $1,001 - $15,000 ↗
2025-02-13 2025-03-06 John Boozman AR Joint Sale (Full) $1,001 - $15,000 ↗
2024-05-03 2024-06-14 Tommy Tuberville AL Joint Sale (Full) $15,001 - $50,000 ↗
2024-02-27 2024-03-15 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2023-12-20 2024-01-08 John Boozman AR Self Purchase $1,001 - $15,000 ↗
2023-12-18 2024-01-12 Shelley Moore Capito WV Spouse Sale (Partial) $1,001 - $15,000 ↗
2023-12-14 2024-01-17 Jerry Moran KS Self Sale (Full) $1,001 - $15,000 ↗
2023-12-11 2024-01-18 Sheldon Whitehouse RI Self Sale (Full) $1,001 - $15,000 ↗
2023-07-25 2023-08-14 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2023-06-12 2023-07-14 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2022-01-12 2022-02-14 Tommy Tuberville AL Joint Purchase $1,001 - $15,000 ↗
2021-12-21 2022-01-21 Jerry Moran KS Spouse Purchase $1,001 - $15,000 ↗
2020-07-09 2020-08-04 Thomas R. Carper DE Spouse Purchase $1,001 - $15,000 ↗
2020-04-14 2021-05-02 David Perdue — Joint Sale (Full) $100,001 - $250,000 ↗
2020-04-07 2020-05-01 Kelly Loeffler GA Joint Sale (Full) $100,001 - $250,000 ↗
2020-04-03 2020-05-08 David Perdue — Joint Sale (Partial) $1,001 - $15,000 ↗
2020-02-28 2021-05-02 David Perdue — Joint Purchase $15,001 - $50,000 ↗
2020-02-28 2021-05-02 David Perdue — Joint Purchase $1,001 - $15,000 ↗
House Trading Activity
Transaction Date Disclosed Representative District Owner Type Amount Link
2026-02-10 2026-03-10 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-12-31 2026-01-23 James French Hill AR02 — Sale (Full) $100,001 - $250,000 ↗
2025-12-19 2026-01-12 Gilbert Cisneros CA31 — Sale (Partial) $1,001 - $15,000 ↗
2025-11-18 2025-12-15 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-09-15 2025-10-03 Ro Khanna CA17 — Sale $1,001 - $15,000 ↗
2025-09-05 2025-10-03 Ro Khanna CA17 — Sale $1,001 - $15,000 ↗
2025-08-05 2025-09-12 Gilbert Cisneros CA31 — Sale (Partial) $1,001 - $15,000 ↗
2025-07-16 2025-08-13 Lisa McClain MI09 Spouse Purchase $1,001 - $15,000 ↗
2025-06-17 2026-01-13 Julia Letlow LA05 — Purchase $1,001 - $15,000 ↗
2025-06-03 2025-07-17 Josh Gottheimer NJ05 Joint Sale $1,001 - $15,000 ↗
2025-05-30 2025-06-06 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-05-30 2025-06-09 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-05-15 2025-06-02 Rob Bresnahan PA08 — Purchase $15,001 - $50,000 ↗
2025-04-29 2025-05-07 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
2025-04-21 2025-05-13 Bruce Westerman AR04 — Sale $1,001 - $15,000 ↗
2025-04-08 2025-04-29 Rob Bresnahan PA08 — Sale $15,001 - $50,000 ↗
2025-03-31 2025-04-07 Gilbert Cisneros CA31 — Sale (Full) $15,001 - $50,000 ↗
2025-03-10 2025-04-11 Carol Devine Miller WV01 — Sale (Full) $1,001 - $15,000 ↗
2025-03-03 2025-04-17 Bruce Westerman AR04 — Purchase $1,001 - $15,000 ↗
2025-02-26 2025-03-07 Gilbert Cisneros CA31 — Purchase $1,001 - $15,000 ↗
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General